Selected research
Industry Research
Haemophilia Treatment Industry Research Report 2026
Market perspective
The global Haemophilia Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Haemophilia Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Haemophilia Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Haemophilia Treatment include Takeda, Novo Nordisk, Roche, Pfizer, Bayer, Dimension Therapeutics, CSL Behring, Catalyst BioSciences and Aptevo Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Haemophilia Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Haemophilia Treatment Market by Company
Takeda
Novo Nordisk
Roche
Pfizer
Bayer
Dimension Therapeutics
CSL Behring
Catalyst BioSciences
Aptevo Therapeutics
Alnylam Pharmaceuticals
Haemophilia Treatment Segment by Type
Haemophilia A
Haemophilia B
Haemophilia Treatment Segment by Application
Hospital
Pharmaceutical Companies
Other
Haemophilia Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Haemophilia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilia Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Haemophilia Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Haemophilia Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Haemophilia Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Haemophilia A
- Haemophilia B
Applications
- Hospital
- Pharmaceutical Companies
- Other
Companies covered
- Takeda
- Novo Nordisk
- Roche
- Pfizer
- Bayer
- Dimension Therapeutics
- CSL Behring
- Catalyst BioSciences
- Aptevo Therapeutics
- Alnylam Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Haemophilia Treatment Market Size (2021-2032)
- 2.2.2 Global Haemophilia Treatment Sales (2021-2032)
- 2.2.3 Global Haemophilia Treatment Market Average Price (2021-2032)
- 2.3 Haemophilia Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Haemophilia A
- 2.3.3 Haemophilia B
- 2.4 Haemophilia Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmaceutical Companies
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Haemophilia Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Haemophilia Treatment Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Haemophilia Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Haemophilia Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Haemophilia Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Haemophilia Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Haemophilia Treatment, Product Type & Application
- 3.8 Global Manufacturers of Haemophilia Treatment, Established Date
- 3.9 Global Haemophilia Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Haemophilia Treatment Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Novo Nordisk
- 4.2.1 Novo Nordisk Company Information
- 4.2.2 Novo Nordisk Business Overview
- 4.2.3 Novo Nordisk Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novo Nordisk Haemophilia Treatment Product Portfolio
- 4.2.5 Novo Nordisk Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche Haemophilia Treatment Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Haemophilia Treatment Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Bayer
- 4.5.1 Bayer Company Information
- 4.5.2 Bayer Business Overview
- 4.5.3 Bayer Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bayer Haemophilia Treatment Product Portfolio
- 4.5.5 Bayer Recent Developments
- 4.6 Dimension Therapeutics
- 4.6.1 Dimension Therapeutics Company Information
- 4.6.2 Dimension Therapeutics Business Overview
- 4.6.3 Dimension Therapeutics Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Dimension Therapeutics Haemophilia Treatment Product Portfolio
- 4.6.5 Dimension Therapeutics Recent Developments
- 4.7 CSL Behring
- 4.7.1 CSL Behring Company Information
- 4.7.2 CSL Behring Business Overview
- 4.7.3 CSL Behring Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CSL Behring Haemophilia Treatment Product Portfolio
- 4.7.5 CSL Behring Recent Developments
- 4.8 Catalyst BioSciences
- 4.8.1 Catalyst BioSciences Company Information
- 4.8.2 Catalyst BioSciences Business Overview
- 4.8.3 Catalyst BioSciences Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Catalyst BioSciences Haemophilia Treatment Product Portfolio
- 4.8.5 Catalyst BioSciences Recent Developments
- 4.9 Aptevo Therapeutics
- 4.9.1 Aptevo Therapeutics Company Information
- 4.9.2 Aptevo Therapeutics Business Overview
- 4.9.3 Aptevo Therapeutics Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Aptevo Therapeutics Haemophilia Treatment Product Portfolio
- 4.9.5 Aptevo Therapeutics Recent Developments
- 4.10 Alnylam Pharmaceuticals
- 4.10.1 Alnylam Pharmaceuticals Company Information
- 4.10.2 Alnylam Pharmaceuticals Business Overview
- 4.10.3 Alnylam Pharmaceuticals Haemophilia Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Alnylam Pharmaceuticals Haemophilia Treatment Product Portfolio
- 4.10.5 Alnylam Pharmaceuticals Recent Developments
5 Global Haemophilia Treatment Market Scenario by Region
- 5.1 Global Haemophilia Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Haemophilia Treatment Sales by Region: 2021-2032
- 5.2.1 Global Haemophilia Treatment Sales by Region: 2021-2026
- 5.2.2 Global Haemophilia Treatment Sales by Region: 2027-2032
- 5.3 Global Haemophilia Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Haemophilia Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Haemophilia Treatment Revenue by Region: 2027-2032
- 5.4 North America Haemophilia Treatment Market Facts & Figures by Country
- 5.4.1 North America Haemophilia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Haemophilia Treatment Sales by Country (2021-2032)
- 5.4.3 North America Haemophilia Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Haemophilia Treatment Market Facts & Figures by Country
- 5.5.1 Europe Haemophilia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Haemophilia Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Haemophilia Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Haemophilia Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Haemophilia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Haemophilia Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Haemophilia Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Haemophilia Treatment Market Facts & Figures by Country
- 5.7.1 South America Haemophilia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Haemophilia Treatment Sales by Country (2021-2032)
- 5.7.3 South America Haemophilia Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Haemophilia Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Haemophilia Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Haemophilia Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Haemophilia Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Haemophilia Treatment Sales by Type (2021-2032)
- 6.1.1 Global Haemophilia Treatment Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Haemophilia Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Haemophilia Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Haemophilia Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Haemophilia Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Haemophilia Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Haemophilia Treatment Sales by Application (2021-2032)
- 7.1.1 Global Haemophilia Treatment Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Haemophilia Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Haemophilia Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Haemophilia Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Haemophilia Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Haemophilia Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Haemophilia Treatment Value Chain Analysis
- 8.1.1 Haemophilia Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Haemophilia Treatment Production Mode & Process
- 8.2 Haemophilia Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Haemophilia Treatment Distributors
- 8.2.3 Haemophilia Treatment Customers
9 Global Haemophilia Treatment Analyzing Market Dynamics
- 9.1 Haemophilia Treatment Industry Trends
- 9.2 Haemophilia Treatment Industry Drivers
- 9.3 Haemophilia Treatment Industry Opportunities and Challenges
- 9.4 Haemophilia Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst